Skip to main content
. 2014 Jan 12;8(1):31–34. doi: 10.7860/JCDR/2014/6359.3908

[Table/Fig-4]:

Efficacy and safety endpoints in enoxaparin and fondaparinux groups at day 9 and 30. *p>0.05

Study Out come Enoxaparin (n 90) Fondaparinux(n90)
Day 9 Day 30 Day 9 Day 30
Recovery 81(90%) 76(84.4%) 85(94.4%) 87(96.7%)
Recurrent MI/Angina 6(6.6%) 4(4.4%) 4(4.4%) 3(3.3%)
Haemorrhage 3(3.3%) 10(11.1%) 1(1.1%) 0*
Death 0 0 0 0